Editorials The production of generic drugs in India BMJ 2011; 342 doi: https://doi.org/10.1136/bmj.d1694 (Published 22 March 2011) Cite this as: BMJ 2011;342:d1694 Article Related content Metrics Responses Peer review Related articles News Legal challenge to India’s patent laws threatens access to generic drugs, says charity Published: 09 September 2011; BMJ 343 doi:10.1136/bmj.d5753 News Roche’s decision to drop Herceptin patent in India opens way for generics Published: 19 August 2013; BMJ 347 doi:10.1136/bmj.f5197 Letter Benefits of EU-India free trade agreement Published: 18 April 2011; BMJ 342 doi:10.1136/bmj.d2439 See more Trump chooses Obamacare opponent to lead Health and Human Services BMJ November 30, 2016, 355 i6469; DOI: https://doi.org/10.1136/bmj.i6469 Drug firms need to tackle affordability BMJ November 14, 2016, 355 i6096; DOI: https://doi.org/10.1136/bmj.i6096 World Medical Association’s tainted president, Ketan Desai BMJ November 10, 2016, 355 i5867; DOI: https://doi.org/10.1136/bmj.i5867 Cancer drugs, survival, and ethics BMJ November 09, 2016, 355 i5792; DOI: https://doi.org/10.1136/bmj.i5792 WHO refers $29m Oxford research project to GMC for misconduct BMJ November 07, 2016, 355 i5971; DOI: https://doi.org/10.1136/bmj.i5971 Cited by... Minimum manufacturing costs, national prices and estimated global availability of new repurposed therapies for COVID-19Abstract Fulltext PDF Roche's decision to drop Herceptin patent in India opens way for genericsAbstract Fulltext PDF Benefits of EU-India free trade agreementAbstract Fulltext PDF